Tadalafil for Treatment of Fetal Growth Restriction: A Review of Experimental and Clinical Studies

Shintaro Maki,Sho Takakura,Makoto Tsuji,Shoichi Magawa,Yuya Tamaishi,Masafumi Nii,Michiko Kaneda,Kenta Yoshida,Kuniaki Toriyabe,Eiji Kondo,Tomoaki Ikeda
DOI: https://doi.org/10.3390/biomedicines12040804
IF: 4.757
2024-04-05
Biomedicines
Abstract:Fetal growth restriction (FGR) is a major concern in perinatal care. Various medications have been proposed as potential treatments for this serious condition. Nonetheless, there is still no definitive treatment. We studied tadalafil, a phosphodiesterase-5 inhibitor, as a therapeutic agent for FGR in clinical studies and animal experiments. In this review, we summarize our preclinical and clinical data on the use of tadalafil for FGR. Our studies in mouse models indicated that tadalafil improved FGR and hypertensive disorders of pregnancy. A phase II trial we conducted provided evidence supporting the efficacy of tadalafil in prolonging pregnancy (52.4 vs. 36.8 days; p = 0.03) and indicated a good safety profile for fetuses and neonates. Fetal, neonatal, and infant mortality was significantly lower in mothers receiving tadalafil treatment than that in controls (total number: 1 vs. 7, respectively; p = 0.03), and no severe adverse maternal events associated with tadalafil were observed. Although further studies are needed to establish the usefulness of tadalafil in FGR treatment, our research indicates that the use of tadalafil in FGR treatment may be a paradigm shift in perinatal care.
biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
What problem does this paper attempt to address?
The paper attempts to address the issue of treating Fetal Growth Restriction (FGR). FGR is a major concern in perinatal care, associated with perinatal mortality and morbidity, and can lead to neurodevelopmental disorders in infants, such as cerebral palsy and pervasive developmental disorders. Additionally, FGR may increase the risk of cardiovascular diseases and diabetes. Currently, there is no definitive treatment for this severe condition. Researchers have explored the possibility of using the phosphodiesterase-5 (PDE5) inhibitor Tadalafil as a treatment for FGR, evaluating its efficacy and safety through clinical studies and animal experiments. The paper summarizes the effects of Tadalafil in improving FGR and hypertensive disorders of pregnancy, as well as its potential role in prolonging pregnancy and reducing fetal and neonatal mortality. Although further research is needed to confirm the efficacy of Tadalafil in the treatment of FGR, existing study results suggest that Tadalafil may represent a new therapeutic paradigm in perinatal care.